Agalsidase-beta therapy for advanced Fabry disease: a randomized trial
View abstract on PubMed
Summary
This summary is machine-generated.Agalsidase beta treatment demonstrated a trend in delaying major clinical events in advanced Fabry disease patients. Early intervention with agalsidase beta may offer greater benefits before irreversible organ damage occurs.
Area Of Science
- Rare genetic disorders
- Lysosomal storage diseases
- Enzyme replacement therapy
Background
- Fabry disease is a rare, X-linked lysosomal storage disorder caused by alpha-galactosidase A deficiency.
- It can lead to severe renal, cardiac, and cerebrovascular complications, potentially causing early death.
Purpose Of The Study
- To evaluate if agalsidase beta can delay a composite clinical outcome in patients with advanced Fabry disease.
- Assessing the impact on renal, cardiovascular, and cerebrovascular events, as well as mortality.
Main Methods
- A randomized, double-blind, placebo-controlled trial involving 82 adults with mild to moderate kidney disease across 41 international centers.
- Patients received intravenous agalsidase beta (1 mg/kg) or placebo every two weeks for up to 35 months.
- The primary endpoint was the time to the first clinical event (renal, cardiac, cerebrovascular, or death).
Main Results
- Agalsidase beta showed a trend towards delaying the primary composite clinical outcome (HR, 0.47; P=0.06) in the intention-to-treat analysis.
- Secondary analyses in protocol-adherent patients indicated a significant delay (HR, 0.39; P=0.034).
- Larger treatment effects were observed in patients with higher baseline estimated glomerular filtration rates (eGFR > 55 mL/min/1.73 m²).
Conclusions
- Agalsidase beta therapy demonstrated a potential to slow disease progression in advanced Fabry disease.
- The study suggests that initiating therapeutic intervention before irreversible organ damage may yield greater clinical benefits.
- Limitations include a small sample size and a relatively low event rate.